Gene Therapy Trial Results for Retinitis Pigmentosa Published in NEJM

GenSight Biologics and 15-20 National Hospital announced the publication of Phase 1/2 trial results for GS030, an optogenetics gene therapy for late-stage retinitis pigmentosa, in The New England Journal of Medicine. The study detailed primary safety findings and exploratory visual function assessments. This publication marks a significant step in validating the potential of this novel treatment approach for a debilitating eye condition.